NeuBase Makes Strategic Move; EZ Detect's Expanded Reach Fuels Biomerica
- August 03rd, 2023
- 411 views
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) announced a pause in its program development. Instead, NeuBase will explore strategic options, including acquisitions, mergers, and other transactions, with the goal of maximizing shareholder value.
According to the company, the outcome of this evaluation process remains uncertain, and there is no guarantee that any particular course of action will be taken.
$NBSE was trading at $1.26 in pre-market, up $0.02 (+1.61%).
In other news, Biomerica, Inc. (Nasdaq: BMRA) said that CVS Pharmacy has initiated the nationwide rollout of the Company's EZ Detect colorectal disease screening test across more than 7,000 CVS Pharmacy locations.
The EZ Detect product is expected to be available for purchase starting September, following its distribution to CVS Health centers. Moreover, Biomerica is collaborating with CVS Health to introduce another of its products in CVS pharmacies.
In pre-market, $BMRA was trading at $2.00, reflecting a gain of $0.54 (+36.98%) following the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login